Application of Silvestrol in preparation of medicine for treating upper gastrointestinal diseases caused by helicobacter pylori infection

Abstract

The invention discloses an application of Silvestrol in preparation of a medicine for treating upper gastrointestinal diseases caused by helicobacter pylori infection. An in-vitro co-culture mode is established by using neutrophils and helicobacter pylori. The application method comprises: simulating an apoptosis signal path of neutrophils at an in-vivo gastric mucosa helicobacter pylori infectedpart, and comparing the apoptosis condition of neutrophils and the expression condition of apoptotic protein in each in-vitro culture experiment group to determine that after helicobacter pylori infection, continuous infiltration of neutrophils at the helicobacter pylori colonization position is caused by prolonging the apoptosis period of the neutrophils so that it is verified that Silvestrol hasan accurate targeting effect and an effective activation rate on apoptosis of neutrophils, the apoptosis process of neutrophils infiltrated in a helicobacter pylori infection part can be promoted, and the neutrophils in an infection focus are properly removed. A clinical existing antibacterial drug treatment method is replaced, and the generation of drug resistance of helicobacter pylori is reduced.

Description

technical field [0001] The invention relates to the application of Silvestrol in the preparation of medicine for treating upper digestive tract diseases caused by Helicobacter pylori infection. Background technique [0002] Helicobacter pylori is the pathogenic bacteria of chronic active gastritis, which is closely related to peptic ulcer, especially duodenal ulcer. After the human gastric mucosa is infected with Helicobacter pylori, the gastric epithelial cells will undergo signal transduction and cytoskeleton reorganization, release cytokines such as IL-8 and some chemical factors, and promote the migration of neutrophils from the blood vessels to the gastric epithelium to enter the infection. Focus and activate neutrophils to release reactive metabolites and proteolytic enzymes, and kill pathogens through a series of bactericidal functions to maintain body health. After infection with Helicobacter pylori, if no timely eradication treatment is carried out, the bactericida...

AI Technical Summary

Problems solved by technology

In a clinical correlation study, it was found that the infiltration of neutrophils in the gastric mucosal tissue sections of patients with H.

[0003] Clinically, antibiotics and chemically synthesized drugs are mainly used to kill Helicobacter pylori, but with the abuse of antibiotics in humans, for example, the use of antibiotic triple therapy (such as antibiotics + metronidazole + bismuth), resulting in the gradual emergence of resistant strains of Helicobacter pylori , making the application of this therapy gradually limited

Images